Tegavivint for the Treatment of Relapsed or Refractory Leukemia
Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is to find out the best dose and side effects of tegavivint in treating
patients with leukemia that has come back (relapsed) or does not response to treatment
(refractory). Tegavivint may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. Giving tegavivint in combination with decitabine may help control the
disease.